Brought to you by 
AstraZeneca, Cambridge Antibody enter inflammation alliance
03 Dec 2004
Executive Summary
AstraZeneca and Cambridge Antibody Technology have entered into a five-year co-funded and co-managed project to discover and develop monoclonal antibodies to treat inflammatory (including respiratory) diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com